CD274 and neoplasm: Previous investigations revealed that tTMB—orthogonal to PD‐L1 expression—can serve as a complementary and/or alternative biomarker that may provide predictive value and address the unmet medical need in patient populations currently not being served by ICIs in a tumor‐agnostic manner.24